Cobimetinib for BRAF-wild-type or Mutated Histiocytoses

NCT04007848 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Disease or R Group Histiocytoses

Interventions

DRUG: Cobimetinib
DRUG: Placebo oral tablet

Sponsor

Assistance Publique - Hôpitaux de Paris